Tirzepatide is a dual GIP/GLP-1 receptor agonist that is FDA-approved under the brand names Mounjaro (type 2 diabetes) and Zepbound (weight management). Research-labeled tirzepatide sold outside those approved, pharmacy-dispensed products is not the same regulated pharmaceutical.
FDA-approved — a different evidence tier
Tirzepatide is FDA-approved (Mounjaro for diabetes, Zepbound for obesity), with a large Phase 3 trial program involving thousands of patients — categorically stronger evidence than research-only peptides.
Benefits
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a single molecule activating both incretin hormone pathways.
Type 2 diabetes vs. insulin glargine (n=2,002, 52 weeks): HbA1c reduction of −2.43% (10mg) and −2.58% (15mg) vs. −1.44% for insulin glargine. Hypoglycemia was lower with tirzepatide (6-9%) than glargine (19%). Del Prato et al., SURPASS-4, Lancet, 2021
Obesity, placebo-controlled (n=2,539, 72 weeks): mean weight loss of 15.0% (5mg), 19.5% (10mg), and 20.9% (15mg) vs. 3.1% for placebo (P<0.001 at every dose). 57% of patients on the 15mg dose achieved ≥20% weight loss, vs. 3% on placebo. Jastreboff et al., SURMOUNT-1, N Engl J Med, 2022
Dosage
FDA-labeled dosing: once-weekly subcutaneous injection, 5mg, 10mg, or 15mg, with a 20-week dose-escalation period before reaching maintenance dose in the obesity trial. This is the only compound in this batch with an actual FDA-labeled dose, not a community convention.
Side Effects
Most common: gastrointestinal (nausea, diarrhea, vomiting), predominantly mild to moderate, mainly during dose escalation. Discontinuation due to adverse events: 4.3% (5mg), 7.1% (10mg), 6.2% (15mg), vs. 2.6% placebo. Cardiovascular safety (SURPASS-4): MACE-4 hazard ratio 0.74 vs. insulin glargine — not elevated. Documented but rare: anaphylactic/allergic reactions.
Results Timeline
SURMOUNT-1 (obesity): 72-week trial with a 20-week dose-escalation period — most of the weight-loss curve happens after titration is complete. SURPASS-4 (diabetes): primary HbA1c endpoint at 52 weeks, safety follow-up to 104 weeks.
Is Tirzepatide FDA-approved?+
Yes, as Mounjaro and Zepbound, dispensed by prescription through licensed pharmacies. Research-labeled tirzepatide sold online is not that approved, regulated product.
Why do people buy research-labeled Tirzepatide instead of Mounjaro/Zepbound?+
Most commonly cited reasons are cost and access; the tradeoff is that research-labeled product has not gone through the same manufacturing and quality oversight as the approved pharmaceutical.
What is Tirzepatide approved for?+
Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), each with their own approved dosing protocols set by a prescriber.
Looking for something specific, or placing a wholesale order? Send us a DM or email.